Digitally quantified area of residual tumor after neoadjuvant chemotherapy in HER2-positive breast cancer
The current study suggests that even minimal residual tumor cells in the primary site can significantly impact on prognosis in HER2-positive early breast cancer.
Authors
- Kenichi Harano (ORCID: https://orcid.org/0000-0002-0833-3489)
- Naoya Sakamoto (ORCID: https://orcid.org/0000-0001-6273-0189)
- Nobuaki Matsubara (ORCID: https://orcid.org/0000-0002-9203-4245)
- Toru Mukohara (ORCID: https://orcid.org/0000-0002-8573-418X)
- Genichiro Ishii (ORCID: https://orcid.org/0000-0001-8637-3323)
- Chikako Funasaka (ORCID: https://orcid.org/0000-0003-0585-4884)
- Masashi Wakabayashi (ORCID: https://orcid.org/0009-0001-6368-5671)
- Yoichi Naito (ORCID: https://orcid.org/0000-0002-8490-9064)
- Hirohiko Miyake
- Chihiro Kondoh (ORCID: https://orcid.org/0000-0001-6189-4851)
- Tatsuya Onishi (ORCID: https://orcid.org/0000-0002-0821-8595)
- Motohiro Kojima (ORCID: https://orcid.org/0000-0002-6150-6545)
- Ako Hosono
- Hiromichi Nakajima (ORCID: https://orcid.org/0000-0001-6401-4258)
- Mao Uematsu
Institutions
- Juntendo University (JP)
- National Cancer Center (US)
- National Cancer Center Hospital East (JP)
- Japan Clinical Cancer Research Organization (JP)
Publication Details
- Journal
- Breast Cancer
- Published
- 2025-04-02
- DOI
- https://doi.org/10.1007/s12282-025-01694-7
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00